English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

vi21 NEURO-ONCOLOGY • NOVEMBER 2016 group, DCI showed 27 months of survival advantage (wilcoxon p = 0.019) compared to control group. CONCLUSION: Dendritic cell-based Immunotherapy in patients with primary glioblastoma is comparative safe and had minor adverse reactions. DCI results in a longer PFS and OS compared to histological reference and well-tolerated. DCI is a good complementary treatment for primary glioblastoma. ATIM-15. A PHASE I TRIAL OF HYPOFRACTIONATED STEREOTACTIC IRRADIATION (HFSRT) WITH PEMBROLIZUMAB AND BEVACIZUMAB IN patients with recurrent high grade gliomas Solmaz Sahebjam MD1, Peter A. Johnstone1, Peter Forsyth1, John Arrington1, Michael Jaglal1, Nam D. Tran1, Frank D. Vrionis1, Arnold B. Etame1, Melissa Wicklund1, Anise L. Elie1, Tyra Gatewood1, Robert Macaulay2, Prakash Chinnaiyan3 and Michael Yu1; 1H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA, 2Department of Anatomic Pathology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA, 3Department of Radiation Oncology, Beaumont Health and Oakland University School of Medicine, Royal Oak, MI, USA BACKGROUND: High grade gliomas carry a grim prognosis despite current therapies. Expression of PD-1 and PD-L1 is found in the microenvironment of most high grade gliomas. There is strong pre-clinical evidence for the combination of anti PD-1/PD-L1 blockade with radiotherapy and anti-angiogenic agents. This study evaluates the combination of pembrolizumab, an anti-PD-1 monoclonal antibody, with hypofractionated stereotactic irradiation (HFSRT) and bevacizumab. METHODS: This phase I study (3+3 design) explores the safety, tolerability, recommended phase II dose (RP2D), and antitumor activity of pembrolizumab administered concurrently with HFSRT and bevacizumab (NCT02313272). Adult patients with recurrent glioblastoma (GBM) or anaplastic astrocytoma (maximum diameter of target lesion ≤ 3.5 cm) are eligible. Eligible patients receive HFSRT to the recurrent tumor (30 Gy delivered in 5 fractions) combined with bevacizumab (10 mg/kg, intravenously Q2W) and pembrolizumab (100 mg or 200 mg intravenously based on dose level, Q3W). Two dose levels of pembrolizumab (100 mg and 200 mg Q3W) are explored. After determination of RP2D, an additional 20 patients will be enrolled in an expansion cohort. Response is assessed every 6W per RANO criteria. Effect of treatment on quality of life measures are evaluated. RESULTS: As of June 2016, dose escalation cohort has been completed and accrual to dose expansion cohort is ongoing. Combination of HFSRT (30 Gy in 5 fractions) with pembrolizumab (200 mg every 3 weeks) and bevacizumab (10 mg/kg every 2 weeks) is well tolerated. No dose limiting toxicity or treatmentrelated neurologic adverse event has been observed. Six out of nine patients have achieved objective response (complete response + partial response). CONCLUSION: Preliminary data demonstrate an acceptable toxicity profile and encouraging anti-tumor activity. Updated safety and efficacy data

neuro-oncology

ATIM-16. NIVOLUMAB COMBINED WITH RADIOTHERAPY WITH OR WITHOUT TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA: RESULTS FROM PHASE 1 SAFETY COHORTS IN CHECKMATE 143